Bryan, Garnier & Co advises Bone Therapeutics on its €19.45 million convertible bond placement

Bryan, Garnier & Co advises Bone Therapeutics on its €19.45 million convertible bond placement

News published on March Monday 12, 2018
Share on


Bone Therapeutics is a bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases.

They announced positive interim results for its ALLOB Phase I/IIA delayed-union study and its ALLOB Phase IIA spinal fusion study.

The fundraising was required to finance ongoing R&D programs.

Interim results for the PREOB Osteonecrosis study and launch of ALLOB Ph IIB are expected in 2018 H2.

Transactional highlights

Bryan, Garnier & Co acted as the Sole Bookrunner for the offering.

A total amount of €19.45 million in committed capital has been subscribed during the offering.

The flexible convertible bond product allowed for immediate conversion into ordinary shares and/or differed investments.

The accelerated bookbuilding offering was open to institutional investors and private investors.

Convertible bonds and/or new ordinary shares were issued at a 8% discount.

About Bone Therapeutics

Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.

Their technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into “osteoblastic”, or bone-forming cells.

The company’s primary clinical focus is ALLOB®, an allogeneic “off-the-shelf” cell therapy product derived from stem cells of healthy donors, additionally they also have an autologous bone cell therapy product, PREOB®, obtained from patient’s own bone marrow and currently in Phase III development for osteonecrosis of the hip.


About Bryan, Garnier & Co

Bryan, Garnier & Co is a European, full service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Media & Telecoms, Healthcare, Smart Industries & Energy, Consumer, Brands & Retail and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Zurich and New York. The firm is a member of the London Stock Exchange and Euronext.


Deal team

Hervé Ronin
T: +33 1 70 36 57 22  

Dr Anne Moore
Vice President
T: +33 1 56 68 75 39

Jean de Pracomtal
T: + 33 1 56 68 75 38

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities